Amedeo Smart

Free Medical Literature Service

 

Amedeo

Colorectal Neoplasms
  Free Subscription

Articles published in
Eur J Cancer
    December 2025
  1. WERF-'T LAM AV, Dowty JG, Italia M, Bakker AC, et al
    Cancer risks for MSH6 pathogenic variant carriers.
    Eur J Cancer. 2025;231:116098.
    >> Share

  2. VANDE KERCKHOVE FEC, van den Berg K, van Erning FN, Daniels-Gooszen AW, et al
    Implications of inaccurate lymph node staging in early and intermediate-risk rectal cancer on survival-related outcomes in a large Dutch population-based cohort.
    Eur J Cancer. 2025;231:116052.
    >> Share

    November 2025
  3. ZHANG R, Li H, Ding L, Liu H, et al
    Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study.
    Eur J Cancer. 2025;230:116056.
    >> Share

  4. CERVANTES B, Grosnon C, Samaille T, Mas L, et al
    Patterns of progressive disease in patients with microsatellite instability-high (MSI-H) metastatic colorectal cancer treated with immune checkpoint inhibitor(s): Different entities requiring tailored management.
    Eur J Cancer. 2025;232:116119.
    >> Share

  5. WEISS L, Stintzing S, Modest DP, Stahler A, et al
    First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF(V600E)-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (
    Eur J Cancer. 2025;232:116105.
    >> Share

  6. MIRANDOLA A, Cartry J, Bedja S, Pisareva E, et al
    Characterization of the cell-free DNA released by tumor organoids derived from colorectal cancer patients.
    Eur J Cancer. 2025;231:116097.
    >> Share

  7. BREGNI G, Leurquin B, Giasafaki P, Takemura N, et al
    Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis.
    Eur J Cancer. 2025;231:116092.
    >> Share

    October 2025
  8. KIM Y, Kim EY, Kim MY, Cho BH, et al
    Immune-enhanced machine learning approach for early detection of precancerous colorectal neoplasia: Insights from biomarkers in routine health checkups.
    Eur J Cancer. 2025;229:115786.
    >> Share

  9. YAMAMOTO K, Bando H, Misumi T, Nishikawa T, et al
    Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study.
    Eur J Cancer. 2025;230:116034.
    >> Share

    September 2025
  10. BERGEN ES, Le Malicot K, Taieb J
    Response to letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115798.
    >> Share

  11. LIU J, Yang S, Zhang G
    Letter Re: Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;230:115797.
    >> Share

  12. ONDER AH, Catli MM
    Colorectal cancer treatment commentary review.
    Eur J Cancer. 2025;230:115809.
    >> Share

  13. BATTAGLIN F, O'Neil BH, Stintzing S, Ou FS, et al
    Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).
    Eur J Cancer. 2025;227:115694.
    >> Share

  14. DASARI A, Eng C, Lonardi S, Garcia-Carbonero R, et al
    Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.
    Eur J Cancer. 2025;227:115641.
    >> Share

  15. LANGHEINRICH M, Gerken M, Robers G, Hansinger J, et al
    Survival benefit of adjuvant chemotherapy in elderly patients with UICC stage III colon carcinoma: A 20-year population-based German cohort study.
    Eur J Cancer. 2025;227:115583.
    >> Share

    August 2025
  16. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    >> Share

  17. HAN L, Josephs D, McDonald L, Gomm L, et al
    The effect of centralising novel cell therapies for solid cancers - a health systems planning model for Europe.
    Eur J Cancer. 2025;226:115594.
    >> Share

  18. MICHIEL ZEEUW J, Kemna R, Ali M, van Eck S, et al
    Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.
    Eur J Cancer. 2025;228:115738.
    >> Share

  19. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    >> Share

  20. ANTONIOTTI C, Marmorino F, Rossini D, Schmoll HJ, et al
    FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials.
    Eur J Cancer. 2025;228:115713.
    >> Share

    July 2025
  21. CIARDIELLO D, Boscolo Bielo L, Napolitano S, Cioli E, et al
    Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.
    Eur J Cancer. 2025;226:115642.
    >> Share

  22. TAIEB J, Modest DP, Fakih M, Ciardiello F, et al
    Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
    Eur J Cancer. 2025;227:115644.
    >> Share

  23. GALLOIS C, Ambrosini M, Lonardi S, Alouani E, et al
    Prognostic impact of the BRAF V600E mutation in patients with MSI-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Eur J Cancer. 2025;227:115645.
    >> Share

  24. BERGEN ES, Canton C, Boulin M, Le Malicot K, et al
    Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial.
    Eur J Cancer. 2025;227:115643.
    >> Share

  25. VAN DRIEL MHE, Wullaert L, Voigt KR, Outmani L, et al
    Patient-led follow-up after curative colorectal cancer surgery: The primary outcome analysis of the prospective, multicentre FUTURE-primary implementation study.
    Eur J Cancer. 2025;226:115599.
    >> Share

    June 2025
  26. LIU R, Yin X, Bai Y, Zhong H, et al
    A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.
    Eur J Cancer. 2025;226:115566.
    >> Share

  27. SHAMSEDDINE A, Turfa R, Chehade L, Zeidan YH, et al
    Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced microsatellite stable rectal adenocarcinoma: The Averectal study.
    Eur J Cancer. 2025;222:115428.
    >> Share

    May 2025
  28. HAFLIGER E, Nili-Asgari R, Netter J, Taieb J, et al
    Case report of two fatal cerebral hemorrhages in patients with metastatic colorectal cancer treated with Fruquintinib.
    Eur J Cancer. 2025 May 19:115517. doi: 10.1016/j.ejca.2025.115517.
    >> Share

    April 2025
  29. MORETTO R, Rossini D, Polito MG, Antoniotti C, et al
    The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies.
    Eur J Cancer. 2025;222:115470.
    >> Share

  30. PIZZAMIGLIO M, Soulabaille A, Lahlou W, Pilla L, et al
    Advances and challenges in targeted therapies for HER2-amplified colorectal cancer.
    Eur J Cancer. 2025;222:115471.
    >> Share

  31. NORONHA MM, Costa Almeida LF, Cappellaro AP, Silva LFLD, et al
    Neoadjuvant chemotherapy for colon cancer: A systematic review and meta-analysis of randomized controlled trials.
    Eur J Cancer. 2025;222:115476.
    >> Share

  32. JORGENSEN SF, Njor SH, Nevala A, Palsson B, et al
    Nordic colorectal cancer screening programmes: A comparison of organization, operation, and quality indicators.
    Eur J Cancer. 2025;222:115444.
    >> Share

  33. WEISS L, Stintzing S, Stahler A, Benedikt Westphalen C, et al
    Molecular hyperselection for optimal choice of first-line targeted therapy independent of primary tumor sidedness: An exploratory analysis of the randomized FIRE-3 study performed in RAS wild-type metastatic colorectal cancer.
    Eur J Cancer. 2025;221:115399.
    >> Share

    March 2025
  34. HOLCH JW, Ohnmacht AJ, Stintzing S, Heinrich K, et al
    FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
    Eur J Cancer. 2025;220:115388.
    >> Share

  35. MORETTO R, Boccaccio C, Landi M, Masi G, et al
    Total neoadjuvant treatment, non-operative management and radiotherapy-free strategies: New approaches for the management of proficient mismatch repair/microsatellite stable locally advanced rectal cancer. A narrative review and evidence-based algorit
    Eur J Cancer. 2025;218:115261.
    >> Share

  36. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    >> Share

    February 2025
  37. POUMEAUD F, Valentin T, Fares N, Segier B, et al
    Sarcomas developed in patients with Lynch Syndrome are enriched in pleomorphic soft-tissue sarcomas and are sensitive to immunotherapy.
    Eur J Cancer. 2025;216:115196.
    >> Share

  38. QIU X, Zhou J, Qiu H, Shen Z, et al
    A new treatment strategy for mid-low rectal cancer patients exhibiting a clinical complete or near-complete response to neoadjuvant chemoradiotherapy: Transanal endoscopic microsurgery --A multicenter prospective case-control clinical trial by MONT-R.
    Eur J Cancer. 2025;216:115156.
    >> Share

    January 2025
  39. SOBRERO A, Dasari A, Aquino J, Lonardi S, et al
    Health-related quality of life associated with fruquintinib in patients with metastatic colorectal cancer: Results from the FRESCO-2 study.
    Eur J Cancer. 2025;218:115268.
    >> Share

  40. WANG DS, Pat Fong W, Wen L, Cai YY, et al
    Safety and efficacy of adjuvant FOLFOX/FOLFIRI with versus without hepatic arterial infusion of floxuridine in patients following colorectal cancer liver metastasectomy (HARVEST trial): A randomized controlled trial.
    Eur J Cancer. 2025;214:115154.
    >> Share

    December 2024
  41. CARBONE F, Spinelli A, Ciardiello D, Realis Luc M, et al
    Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
    Eur J Cancer. 2024;215:115172.
    >> Share

  42. TOUGERON D, Bibeau F, Chibaudel B, Kim S, et al
    Resection of colorectal liver metastases with second-line aflibercept plus FOLFIRI: Results from the RESECTION prospective French cohort.
    Eur J Cancer. 2024;213:115082.
    >> Share

    November 2024
  43. HIRANO H, Kataoka K, Yamaguchi T, Wagner AD, et al
    Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A).
    Eur J Cancer. 2024;214:115139.
    >> Share

  44. DUNN C, Shapiro J, Lee M, Wong R, et al
    Measuring quality in the care of metastatic colorectal cancer utilising available registry data: A modified Delphi study.
    Eur J Cancer. 2024;214:115142.
    >> Share

  45. XIAO A, Li X, Wang C, Ye J, et al
    Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
    Eur J Cancer. 2024;213:115111.
    >> Share

  46. SUN L, Xu Y, Chen N, Zhang C, et al
    Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial.
    Eur J Cancer. 2024;213:115109.
    >> Share

  47. FRYDENDAHL A, Nors J, Rasmussen MH, Henriksen TV, et al
    Detection of circulating tumor DNA by tumor-informed whole-genome sequencing enables prediction of recurrence in stage III colorectal cancer patients.
    Eur J Cancer. 2024;211:114314.
    >> Share

    October 2024
  48. STINTZING S, Yoshino T
    Response to letter re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;210:114298.
    >> Share

  49. FOKAS E, Williams H, Diefenhardt M, Lin S, et al
    Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials.
    Eur J Cancer. 2024;210:114291.
    >> Share

    September 2024
  50. SMABERS LP, Huismans MA, van Nieuwenhuijzen N, Minnema MC, et al
    Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.
    Eur J Cancer. 2024;212:115059.
    >> Share

  51. MARGALIT O, Stemmer A, Chapin WJ, Shacham-Shmueli E, et al
    Duration of immunotherapy in dMMR/MSI-H metastatic colorectal cancer patients.
    Eur J Cancer. 2024;212:114336.
    >> Share

  52. BOTTA L, Capocaccia R, Bernasconi A, Rossi S, et al
    Estimating cure and risk of death from other causes of cancer patients: EUROCARE-6 data on head & neck, colorectal, and breast cancers.
    Eur J Cancer. 2024;208:114187.
    >> Share

    August 2024
  53. AMBROSINI M, Tougeron D, Modest D, Guimbaud R, et al
    BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer.
    Eur J Cancer. 2024;210:114290.
    >> Share

  54. XIE Z, Lin H, Huang Y, Wang X, et al
    BAP1-mediated MAFF deubiquitylation regulates tumor growth and is associated with adverse outcomes in colorectal cancer.
    Eur J Cancer. 2024;210:114278.
    >> Share

  55. ZHANG P, Han Y, Cai Z, Cao D, et al
    Letter Re: A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024 Aug 6:114266. doi: 10.1016/j.ejca.2024.114266.
    >> Share

  56. MICHIEL ZEEUW J, Wesdorp NJ, Ali M, Bakker AJJ, et al
    Prognostic value of total tumor volume in patients with colorectal liver metastases: A secondary analysis of the randomized CAIRO5 trial with external cohort validation.
    Eur J Cancer. 2024;207:114185.
    >> Share

    July 2024
  57. FRANKEN IA, van der Baan FH, Vink GR, May AM, et al
    Survival and patient-reported outcomes of real-world high-risk stage II and stage III colon cancer patients after reduction of adjuvant CAPOX duration from 6 to 3 months.
    Eur J Cancer. 2024;208:114207.
    >> Share

    June 2024
  58. MERCIER L, Delaye M, Fuerea A, Ducreux M, et al
    Oral ADAGRASIB associated with cetuximab unblocks obstructed colorectal cancer.
    Eur J Cancer. 2024;208:114193.
    >> Share

  59. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    >> Share

  60. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Corrigendum to "Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021'' Volume 205, July 2024, 114104.
    Eur J Cancer. 2024 Jun 11:114155. doi: 10.1016/j.ejca.2024.114155.
    >> Share

  61. COHEN R, Raeisi M, Chibaudel B, Shi Q, et al
    Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.
    Eur J Cancer. 2024;207:114160.
    >> Share

  62. ZWART WH, Temmink SJD, Hospers GAP, Marijnen CAM, et al
    Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.
    Eur J Cancer. 2024;204:114044.
    >> Share

    May 2024
  63. CHEN C, Feng YS, Wang Z, Gupta M, et al
    Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer.
    Eur J Cancer. 2024;207:114147.
    >> Share

  64. TAIEB J, Basile D, Seligmann J, Argiles G, et al
    Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.
    Eur J Cancer. 2024;206:114118.
    >> Share

  65. SWARTJES H, Sijtsma FPC, Elferink MAG, van Erning FN, et al
    Trends in incidence, treatment, and relative survival of colorectal cancer in the Netherlands between 2000 and 2021.
    Eur J Cancer. 2024;205:114104.
    >> Share

  66. MOREAU M, Alouani E, Flecchia C, Falcoz A, et al
    A multicenter study evaluating efficacy of immune checkpoint inhibitors in advanced non-colorectal digestive cancers with microsatellite instability.
    Eur J Cancer. 2024;202:114033.
    >> Share

  67. VAN GEFFEN EGM, Langhout JMA, Hazen SJA, Sluckin TC, et al
    Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
    Eur J Cancer. 2024;202:114021.
    >> Share

    March 2024
  68. TAKASHIMA A, Garcia-Alfonso P, Manneh R, Besen AA, et al
    Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Eur J Cancer. 2024;205:114036.
    >> Share

  69. BARBE R, Belkouchi Y, Menu Y, Cohen R, et al
    Imaging-guided prognostic score-based approach to assess the benefits of combotherapy versus monotherapy with immune checkpoint inhibitors in metastatic MSI-H colorectal cancer patients.
    Eur J Cancer. 2024;202:114020.
    >> Share

  70. SPIEKMAN IAC, Zeverijn LJ, Geurts BS, Verkerk K, et al
    Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP).
    Eur J Cancer. 2024;202:113988.
    >> Share

  71. LI L
    Comment on: Despite multi-disciplinary team discussions the socioeconomic disparities persist in the oncological treatment of non-metastasized colorectal cancer.
    Eur J Cancer. 2024;202:113982.
    >> Share

  72. YOSHINO T, Hooda N, Younan D, Muro K, et al
    A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidedness.
    Eur J Cancer. 2024;202:113975.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016